EID2B

Across TCGA pan-cancer cohorts, EID2B RNA is linked to patient survival in 25 of 34 cancer types, making it the most broadly survival-associated EID2B data layer compared with 1 for mutation status.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher EID2B RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated EID2B expression acts as an unfavorable survival marker, although some lineages such as LUAD and UCS show a favorable association.

LIHC, ACC, and LUAD are the cancer types where EID2B RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Quartile	All	0.395	0.648	<.001	58	view →
ACC	DFS	Tertile	All	0.376	0.816	<.001	54	view →
LUAD	OS	Quartile	All	0.664	0.248	<.001	44	view →
MESO	DFS	Tertile	IV	0.207	0.609	.006	42	view →
UCS	DFS	Quartile	II,III,IV	0.669	0.125	.001	36	view →
STAD	OS	Median	II,III,IV	0.605	0.743	.002	35	view →
PAAD	OS	Tertile	All	0.574	0.268	.003	23	view →
KICH	OS	Tertile	All	0.639	1.000	.012	21	view →
BRCA	OS	Median	IV	0.866	0.364	.001	19	view →
KIRP	DFS	Tertile	IV	0.037	0.529	.010	18	view →
ESCA	DFS	Tertile	All	0.893	0.381	.022	15	view →
KIRC	DFS	Tertile	IV	0.249	0.614	.028	12	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 25 lineages.

EID2B–LIHC (DFS)

Open the LIHC breakdown →